

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449APTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b> Application Number 10/660,131 Filing Date September 11, 2003 First Named Inventor David H. Munn Group Art Unit Unassigned Examiner Name Unassigned R. K. Berry Attorney Docket Number M0351-287806 Express Mail Certificate EV 127 541 682 US	
Sheet	1	of	9

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
R. K. Berry	1.	5,582,831		Shinitzky, Meir	12/10/96	
	2.	5,648,219		MacKay, V.L. et al.	07/15/97	
	3.	5,849,589		Tedder, T.F. et al.	12/15/98	
	4.	5,851,756		Steinman, R.M. et al.	12/22/98	
	5.	5,871,728		Thomson, A.W. et al.	02/15/99	
	6.	5,994,126		Steinman, R.M. et al.	11/30/99	
	7.	6,008,004		Olweus, Johanna et al	12/28/99	
	8.	6,080,409		Laus, R. et al.	06/27/00	
	9.	6,194,204		Crawford, K.D. et al.	02/27/01	
	10.	6,210,662		Laus, R. et al.	04/03/01	
	11.	6,224,859		Thomson, A.W. et al.	05-01-01	
	12.	6,228,640		Cezayirli, C. et al.	05/08/01	
	13.	6,274,378		Steinman, R.M. et al	08/14/01	
	14.	6,290,972	B1	Armitage, R.J. et al.	09/18/01	
	15.	6,395,876		Munn, D. et al.	05-28-02	
	16.	6,451,840	B1	Munn, D. et al.	09-17-02	
	17.	2001/0001040 A1		Munn, D. et al.	05-10-01	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup> (if known)			

Examiner Signature	R. K. Berry	Date Considered	8/22/06
-----------------------	-------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/660,131
		Filing Date	September 11, 2003
		First Named Inventor	David H. Munn
		Group Art Unit	Unassigned
		Examiner Name	Unassigned <i>R. DeBey</i>
		Attorney Docket Number	M0351-287806
Sheet 2 of 9		Express Mail Certificate	EV 127 541 682 US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>MO</i>	18	ALBERT, M. L., Dendritic cell maturation is required for the cross-tolerization of CD8 <sup>+</sup> T cells, <i>Nature Immunol.</i> , <b>2</b> , 1010-1017, 2001	
	19	ALEXANDER, A. M. et al., Indoleamine 2,3-Dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes, <i>Diabetes</i> , <b>51</b> :356-364, 2002	
	20	BANCHEREAU, J. et al., Immune and clinical responses in patients with metastatic melanoma to CD34 <sup>+</sup> progenitor-derived dendritic cell vaccine, <i>Cancer Res.</i> , <b>61</b> , 6451-6458, 2001	
	21	BANKENSTEIN, T. et al, Cross-priming versus cross-tolerance: are two signals enough?, <i>Trends in Immunol.</i> , <b>23</b> , 171-173, 2002	
	22	BAX, A. et al., MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy, <i>J. Magn. Reson.</i> , <b>65</b> : 355-360, 1985	
	23	BELL, D. et al., In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas, <i>J. Exp. Med.</i> , <b>190</b> , 1417-1426, 1999	
	24	BENNETT, S. R. et al., Help for cytotoxic-T-cell responses is mediated by CD40 signalling, <i>Nature</i> , <b>393</b> , 478-480, 1998	
	25	BODENHAUSEN, G. et al., Natural abundance Nitrogen-15 NMR by enhanced heteronuclear spectroscopy, <i>Natural Chem. Phys. Lett.</i> , <b>69</b> : 185-189, 1980	
	26	CADY, S. G. et al., 1-Methyl-DL-tryptophan, $\beta$ -(3-Benzofuranyl)-DL-alanine (the Oxygen Analog of Tryptophan), and $\beta$ -[3-Benzo(b)thienyl]-DL-alanine (the Sulfur Analog of Tryptophan) are competitive inhibitors of Indoleamine 2,3-Dioxygenase, <i>Arch. Biochem. Biophys.</i> , <b>291</b> , 326-333, 1991	
	27	CELLA, M. et al., Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation, <i>J. Exp. Med.</i> , <b>184</b> , 747-752, 1996	
<i>MO</i>	28	CELLA, M. et al., Plasmacytoid monocytes migrate to inflamed	

*R M DeBey 8/22/06*

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/660,131
		Filing Date	September 11, 2003
		First Named Inventor	David H. Munn
		Group Art Unit	Unassigned <i>1047</i>
		Examiner Name	Unassigned <i>R. DeBery</i>
		Attorney Docket Number	M0351-287806
Sheet	3 of 9	Express Mail Certificate	EV 127 541 682 US

		lymph nodes and produce large amounts of type I interferon, <i>Nature Medicine</i> , <b>5</b> , 919-923, 1999	
<i>MS</i>	29	CHEN, S., et al., In vivo inhibition of CC and CX3C Chemokine-induced Leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II, <i>J. Exp. Med.</i> , <b>188</b> : 193-198 (1998)	
	30	CHEN, W. et al., TGF- $\beta$ released by apoptotic T cells contributes to an immunosuppressive milieu, <i>Immunity</i> , <b>22</b> :14, 715-725, 2001	
	31	COBBOLD, S. et al., Infectious tolerance, <i>Curr. Opin. Immunol.</i> , <b>10</b> , 518-524, 1998	
	32	CORNILESCU, G. et al., Protein backbone angle restraints from searching a database for chemical shift and sequence homology, <i>J. Biomol. NMR</i> , <b>13</b> : 289-302, 1999	
	33	CURIEL, T. J. et al., Tumor immunotherapy: inching toward the finish line, <i>J. Clin. Invest.</i> , <b>109</b> , 311-312, 2002	
	34	DHODAPKAR, M. V. et al., Mature dendritic cells boost functionally superior CD8 <sup>+</sup> T-cell in humans without foreign helper epitopes, <i>J. Clin. Invest.</i> , <b>105</b> , R9-R14, 2000	
	35	DHODAPKAR, M. V. et al., Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells, <i>J. Exp. Med.</i> , <b>193</b> , 233-238, 2001	
	36	DOAN, T. et al., Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization, <i>Cancer Res.</i> , <b>60</b> , 2810-2815, 2000	
	37	DONG et al., B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, <i>Nature Med.</i> , <b>5</b> , 1365-1369, 1999	
	38	DZIOONEK, A. et al., BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood, <i>J. Immunol.</i> , <b>165</b> , 6037-6046, 2000	
	39	FACCHETTI, F. et al., Plasmacytoid monocytes (so-called plasmacytoid T cells) in Hodgkin's disease, <i>J. Pathol.</i> , <b>158</b> , 57-65, 1989	
	40	FALLARINO, F. et al., Functional expression of indoleamine 2,3-dioxygenase by murine CD8 $\alpha$ <sup>+</sup> dendritic cells, <i>Internat Immunol.</i> , <b>14</b> (1), 65-68, 2002	
<i>MS</i>	41	FIOCCHI, C., TGF- $\beta$ /Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for	

*Rm DeBery*

*8/22/06*

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/660,131
		Filing Date	September 11, 2003
		First Named Inventor	David H. Munn
		Group Art Unit	Unassigned 1647
		Examiner Name	Unassigned R. DeBerno
		Attorney Docket Number	M0351-287806
Sheet 4 of 9	Express Mail Certificate	EV 127 541 682 US	

		chronic inflammation, <i>J. Clin. Invest.</i> , <b>108</b> , 523-526, 2001	
42		GALLUCCI, S. et al., Natural adjuvants: Endogenous activators of dendritic cells, <i>Nat. Med.</i> , <b>5</b> , 1249-1255, 1999	
43		GORCZYNSKI, R. et al., Dendritic cells expressing TGFβ/IL-10, and CHO cells with OX-2, increase graft survival, <i>Transplantation Proceedings</i> , <b>33</b> , 1565-1566, 2001	
44		GROHMANN, U. et al., IL-6 inhibits the tolerogenic function of CD8α <sup>+</sup> dendritic cells expressing indoleamine 2,3-dioxygenase, <i>J. Immunol.</i> , <b>167</b> , 708-714, 2001	
45		GROUARD, G. et al., The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand, <i>J. Exp. Med.</i> , <b>185</b> , 1101-1111, 1997	
46		HEISER, A. et al., Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors, <i>J. Clin. Invest.</i> , <b>109</b> , 409-417, 2002	
47		HONEY, K. et al., Dominant regulation: a common mechanism of monoclonal antibody induced tolerance?, <i>Immunol. Res.</i> , <b>20</b> , 1-14, 1999	
48		HORUZSKO, A. et al., Maturation of antigen presenting cells is compromised in HLA-G transgenic mice, <i>Internat Immunol.</i> , <b>13</b> , 385-394, 2001	
49		HWU, P. et al., Indoleamine 2,3-Dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation, <i>J. Immunol.</i> , <b>164</b> :3596-3599, 2000	
50		IWASAKI, A. et al., Localization of distinct peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3α, MIP-3β, and secondary lymphoid organ chemokine, <i>J. Exp. Med.</i> , <b>191</b> , 1381-1393, 2000	
51		JONULEIT, H. et al., Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions, <i>Eur. J. Immunol.</i> , <b>27</b> , 3135-3142, 1997	
52		JONULEIT, H. et al., Dendritic cells as a tool to induce anergic and regulatory T cells, <i>Trends Immunol.</i> , <b>22</b> , 394-400, 2001	
53		KIKUCHI, T. et al., Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors, <i>Blood</i> , <b>96</b> , 91-99, 2000	
54		KOURILSKY, P. et al., Cytokine fields and the polarization of	

*R M DeBerno* 8/22/06

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/660,131
		Filing Date	September 11, 2003
		First Named Inventor	David H. Munn
		Group Art Unit	Unassigned
		Examiner Name	Unassigned <i>R. O. Berry</i>
		Attorney Docket Number	M0351-287806
Sheet	5 of 9	Express Mail Certificate	EV 127 541 682 US

		the immune response, <i>Trends in Immunol.</i> , <b>22</b> , 502-509, 2001	
<i>7*</i>	55	KUDO, Y. et al., Human placental indoleamine 2,3-dioxygenase: cellular location and characterization of an enzyme preventing fetal rejection, <i>Biochem, Biophys. Acta</i> , <b>1500</b> , 119-124, 2000	
	56	LEE et al., Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division, <i>Immunol.</i> , <b>107</b> : 452-460 (2002)	
	57	LIU, Y. J., Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity, <i>Cell</i> , <b>106</b> , 259-262, 2001	
	58	MALLOY, K. G. et al., Regulatory T cells in the control of immune pathology, <i>Nature Immunol.</i> , <b>2</b> , 816-822, 2001	
	59	MELLOR, A.L. et al., Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy, <i>Nat. Immunol.</i> <b>2</b> : 64-68 (2001)	
	60	MELLOR, A. L. et al., Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses, <i>J. Immunol.</i> , <b>168</b> , 3771-3776, 2002	
	61	MIKI, T. et al., Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts, <i>Transplantation Proceedings</i> , <b>33</b> , 129-130, 2001	
	62	MULLER, A. et al, Involvement of chemokine receptors in breast cancer metastasis, <i>Nature</i> , <b>410</b> : 50-56, 2001	
	63	MUNN, D. H. et al., Prevention of allogeneic fetal rejection by tryptophan catabolism, <i>Science</i> , <b>281</b> , 1191-1193, 1998	
	64	MUNN, D. H. et al., Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase, <i>Science</i> , <b>297</b> , 1867-1870, 2002	
	65	MUNN, D. H. et al., Inhibition of T cell proliferation by macrophage tryptophan catabolism, <i>J. Exp. Med.</i> , <b>189</b> , 1363-1372, 1999	
	66	NEUHAUS, D. et al, <i>The Nuclear Overhauser Effect in Structural and Conformational Analysis</i> , VCH New York, Chapter 8, The Two- Dimensional NOESY Experiment, 1989, pp. 253-305	
	67	OCHSENBEIN, A. F. et al., Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction, <i>Nature</i> , <b>411</b> , 1058-1064, 2001	
	68	OLWEUS, J. et al., Dendritic cell ontogeny: A human dendritic	

*R. O. Berry* 8/22/06

Please type a plus sign (+) inside this box → ☐

PTO/SB/O&A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/660,131
		Filing Date	September 11, 2003
		First Named Inventor	David H. Munn
		Group Art Unit	Unassigned 1/45
		Examiner Name	Unassigned R DeBery
		Attorney Docket Number	M0351-287806
Sheet	6	of	9
		Express Mail Certificate	EV 127 541 682 US

		cell lineage of myeloid origin, <i>Proc. Natl. Acad. Sci. USA</i> , <b>94</b> , 12551-12556, 1997	
69		PALCZEWSKI, K. et al., Crystal structure of rhodopsin: A G protein—coupled receptor, <i>Science</i> <b>289</b> : 739-745, 2000	
70		PICKL, W. F. et al., Molecular and functional characteristics of dendritic cells generated from highly purified CD14 <sup>+</sup> peripheral blood monocytes, <i>J. Immunol.</i> , <b>157</b> , 3850-3859, 1996	
71		PIOTTO, M. et al, Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions, <i>J. Biomol. NMR.</i> , <b>2</b> : 661-665, 1992	
72		REDDY, A. et al., A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells, <i>Blood</i> , <b>90</b> , 3640-3646, 1997	
73		RIDGE, J. P. et al., A conditioned dendritic cell can be a temporal bridge between a CD4 <sup>+</sup> T-helper and a T-killer cell, <i>Nature</i> , <b>393</b> , 474-478, 1998	
74		SAKAGUCHI, S., Regulatory T cells: key controllers of immunologic self-tolerance, <i>Cell</i> , <b>101</b> , 455-458, 2000	
75		SALI, A. et al., Definition of general topological equivalence in protein structures, <i>J. Mol. Biol.</i> , <b>212</b> , 403-428, 1990	
76		SCHOENBERGER, S. P. et al., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions, <i>Nature</i> , <b>393</b> , 480-483, 1998	
77		SHEVACH, E. M., Certified professionals: CD4+CD25+ suppressor T cells, <i>J. Exp. Med.</i> , <b>193</b> , F41-F45, 2001	
78		SHORTMAN, K. et al., Immunity or tolerance? That is the question for dendritic cells, <i>Nature Immunol.</i> , <b>2</b> , 988-989, 2001	
79		SHORTMAN, K. et al., Mouse and human dendritic cell subtypes, <i>Nature Reviews: Immunology</i> , <b>2</b> , 151-161, 2002	
80		SMYTH, M. J., et al., A fresh look at tumor immunosurveillance and immunotherapy, <i>Nature</i> , <b>2</b> , 293-298, 2001	
81		SOTOMAYER, E. J. et al., Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression, <i>Blood</i> , <b>98</b> , 1070-1077, 2001	
82		SOZZANI, S. et al., The role of chemokines in the regulation of dendritic cell trafficking, <i>J. Leukocyte Biol.</i> , <b>66</b> , 1-9, 1999	
83		SPATOLA, A.F. et al, Rediscovering an endothelin antagonist	

*R M DeBery* 8/22/06

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/660,131
		Filing Date	September 11, 2003
		First Named Inventor	David H. Munn
		Group Art Unit	Unassigned <i>1647</i>
		Examiner Name	Unassigned <i>L. DeBery</i>
		Attorney Docket Number	M0351-287806
Sheet	7	of	9
		Express Mail Certificate	EV 127 541 682 US

		(BQ-123): a self-deconvoluting cyclic pentapeptide library, <i>J. Med. Chem.</i> , <b>39</b> : 3842-3846, 1996	
84		SPATOLA, A.F., Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, ed. B. Weinstein et al, New York, Vol. VII, pp. 267-357, 1983	
85		STAVELEY-O'CARROLL, K. et al., Induction of antigen-specific T cell anergy: An early event in the course of tumor progression, <i>Proc. Natl. Acad. Sci. USA</i> , <b>95</b> , 1178-1183, 1998	
86		SUMMERS, K. L. et al., Phenotypic characterization of five dendritic cell subsets in human tonsils, <i>Am. J. Pathol.</i> , <b>159</b> , 285-295, 2001	
87		SUTMULLER, R. P. M. et al., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25 <sup>+</sup> regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses, <i>J. Exp. Med.</i> , <b>194</b> , 823-832, 2001	
88		SZABOLCS, P. et al., Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate, <i>Blood</i> , <b>87</b> , 4520-4530, 1996	
89		TARAZONA, R. et al, Effects of different antigenic microenvironments on the course of CD8 <sup>+</sup> T cell responses in vivo, <i>Int. Immunol.</i> , <b>8</b> , 351-358, 1996	
90		TAYLOR, M. W. et al., Relationship between interferon- $\gamma$ , indoleamine 2,3-dioxygenase, and tryptophan catabolism, <i>FASEB J.</i> , <b>5</b> , 2516-2522, 1991	
91		THOMPSON, A. W. et al., Are dendritic cells the key to liver transplant tolerance?, <i>Immunol. Today</i> , <b>20</b> , 27-31, 1999	
92		TODRYK, S., A sense of tumour for the immune system, <i>Immunol.</i> , <b>107</b> , 1-4, 2002	
93		van ELSAS, A. et al., Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation, <i>J. Exp. Med.</i> , <b>190</b> , 355-366, 1999	
94		van ELSAS, A. et al., Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with	

*RM DeBery*

*8/22/06*

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/660,131
		Filing Date	September 11, 2003
		First Named Inventor	David H. Munn
		Group Art Unit	Unassigned-1643
		Examiner Name	Unassigned-K. DeBem
		Attorney Docket Number	M0351-287806
Sheet 8 of 9	Express Mail Certificate		EV 127 541 682 US

		a B16 melanoma vaccine: comparison of prophylaxis and therapy, <i>J. Exp. Med.</i> , <b>194</b> , 481-489, 2001	
	95	VARONA, R. et al., CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses, <i>J. Clin. Invest.</i> , <b>107</b> , R37-R45, 2001	
	96	WALDMANN, H. et al., Regulating the immune response to transplants: a role for CD4 <sup>+</sup> regulatory cells?, <i>Immunity</i> , <b>14</b> , 399-406, 2001	
	97	WISHART, D.S. et al., 1H, 13C and 15N chemical shift referencing in biomolecular NMR, <i>J. Biomol. NMR</i> , <b>6</b> , 135-140, 1995	
	98	YANG, D. et al., Cutting edge: Immature dendritic cells generated from monocytes in the presence of TGF- $\beta$ 1 express functional C-C chemokine receptor 6, <i>J. Immunol.</i> , <b>163</b> , 1737-1741, 1999	
	99	ZLOTNIK, A. et al., Chemokines: a new classification system and their role in immunity, <i>Immunity</i> , <b>12</b> , 121-127, 2000	
	100	MORITA, Y. et al., Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis, <i>J. Clin. Invest.</i> , <b>107</b> , 1275-1284, 2001	
	101	MORSE, M.A. et al., Technology evaluation: Theratope, Biomira Inc., <i>Curr. Opin. Mol. Ther.</i> , Aug <b>2(4)</b> :453-458, 2000	
	102	MORSE, M. A. et al., Clinical applications of dendritic cell vaccines, <i>Current Opinion in Molecular Therapeutics</i> , <b>2(1)</b> :20-28, 2000	
	103	NAIR, S. K. et al., Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses <i>in vitro</i> using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA, <i>Int. J. Cancer</i> , <b>82</b> , 121-124, 1999	
	104	POLUEKTOVA, L. Y. et al., Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis, <i>J Immunol.</i> , <b>168</b> :3941-3949, 2002	
	105	RONCAROLO, M. G. et al., Differentiation of T regulatory cells by immature dendritic cells, <i>J. Exp. Med.</i> , <b>193</b> , F5-F9, 2001	
	106	YOON, J.-W. et al., Control of autoimmune diabetes in NOD mice by GAD expression or suppression of $\beta$ cells, <i>Science</i> , <b>284</b> , 1183-1187, 1999	

*Handwritten signature and date: 8/22/06*



Please type a plus sign (+) inside this box →



PTO/SB/O&A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449APTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	10/660,131
	Filing Date	September 11, 2003
	First Named Inventor	David H. Munn
	Group Art Unit	Unassigned 1647
	Examiner Name	Unassigned R. DeSerra
	Attorney Docket Number	M0351-287806
Sheet 9 of 9	Express Mail Certificate	EV 127 541 682 US


Examiner Signature		Date Considered	9/22/03
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

3



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	0/660,131
		Filing Date	September 11, 2003
		First Named Inventor	David H. Munn et al.
		Art Unit	1646 1647
		Examiner Name	To be assigned R. DeBerni
Sheet 1	of 2	Attorney Docket Number	CCR6 (M0351/287806)

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
RO	1	US- 5,885,579	03/23/1999	Linsley et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
RO	1	WO 01/17558 A2	03/15/200 1	Schering Corporation		

Examiner Signature		Date Considered	8/22/06
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9189 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Institute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn et al.
Art Unit	1646-1647
Examiner Name	To be assigned R. DeBerg
Attorney Docket Number	CCR6 (M0351/287806)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MD	1	International Search Report mailed 08/19/04 corresponding to PCT/US03/28349 considered DO NOT PRINT	

Examiner  
Signature

R. DeBerg

Date  
Considered

8/22/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

